214 related articles for article (PubMed ID: 17848949)
1. Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel.
Martinelli M; Bonezzi K; Riccardi E; Kuhn E; Frapolli R; Zucchetti M; Ryan AJ; Taraboletti G; Giavazzi R
Br J Cancer; 2007 Oct; 97(7):888-94. PubMed ID: 17848949
[TBL] [Abstract][Full Text] [Related]
2. Potential antagonism of tubulin-binding anticancer agents in combination therapies.
Taraboletti G; Micheletti G; Dossi R; Borsotti P; Martinelli M; Fiordaliso F; Ryan AJ; Giavazzi R
Clin Cancer Res; 2005 Apr; 11(7):2720-6. PubMed ID: 15814654
[TBL] [Abstract][Full Text] [Related]
3. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
4. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
Davis PD; Dougherty GJ; Blakey DC; Galbraith SM; Tozer GM; Holder AL; Naylor MA; Nolan J; Stratford MR; Chaplin DJ; Hill SA
Cancer Res; 2002 Dec; 62(24):7247-53. PubMed ID: 12499266
[TBL] [Abstract][Full Text] [Related]
5. Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126.
Bozec A; Lassalle S; Gugenheim J; Fischel JL; Formento P; Hofman P; Milano G
Br J Cancer; 2006 Sep; 95(6):722-8. PubMed ID: 16940984
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.
Blakey DC; Westwood FR; Walker M; Hughes GD; Davis PD; Ashton SE; Ryan AJ
Clin Cancer Res; 2002 Jun; 8(6):1974-83. PubMed ID: 12060643
[TBL] [Abstract][Full Text] [Related]
7. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma.
Wachsberger PR; Burd R; Marero N; Daskalakis C; Ryan A; McCue P; Dicker AP
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):835-42. PubMed ID: 15701874
[TBL] [Abstract][Full Text] [Related]
8. Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126.
Cullis ER; Kalber TL; Ashton SE; Cartwright JE; Griffiths JR; Ryan AJ; Robinson SP
Microvasc Res; 2006 Mar; 71(2):76-84. PubMed ID: 16530791
[TBL] [Abstract][Full Text] [Related]
9. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors.
Siemann DW; Rojiani AM
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):846-53. PubMed ID: 15936569
[TBL] [Abstract][Full Text] [Related]
10. Augmentation of radiation response with the vascular targeting agent ZD6126.
Hoang T; Huang S; Armstrong E; Eickhoff JC; Harari PM
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1458-65. PubMed ID: 16488554
[TBL] [Abstract][Full Text] [Related]
11. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
12. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
[TBL] [Abstract][Full Text] [Related]
13. Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma.
Fens MH; Hill KJ; Issa J; Ashton SE; Westwood FR; Blakey DC; Storm G; Ryan AJ; Schiffelers RM
Br J Cancer; 2008 Oct; 99(8):1256-64. PubMed ID: 18797467
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.
Evelhoch JL; LoRusso PM; He Z; DelProposto Z; Polin L; Corbett TH; Langmuir P; Wheeler C; Stone A; Leadbetter J; Ryan AJ; Blakey DC; Waterton JC
Clin Cancer Res; 2004 Jun; 10(11):3650-7. PubMed ID: 15173071
[TBL] [Abstract][Full Text] [Related]
15. Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft.
Petrangolini G; Cassinelli G; Pratesi G; Tortoreto M; Favini E; Supino R; Lanzi C; Belluco S; Zunino F
Br J Cancer; 2004 Apr; 90(7):1464-8. PubMed ID: 15054472
[TBL] [Abstract][Full Text] [Related]
16. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
Goto H; Yano S; Matsumori Y; Ogawa H; Blakey DC; Sone S
Clin Cancer Res; 2004 Nov; 10(22):7671-6. PubMed ID: 15570000
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.
Siemann DW; Rojiani AM
Int J Radiat Oncol Biol Phys; 2002 May; 53(1):164-71. PubMed ID: 12007956
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of the vascular-disrupting agent ZD6126 in a murine renal cell carcinoma model.
Medinger M; Esser N; Soltau J; Lehmann KM; Konerding MA; Wolloscheck T; Ryan AJ; Drevs J
Int J Oncol; 2011 Feb; 38(2):455-64. PubMed ID: 21152862
[TBL] [Abstract][Full Text] [Related]
19. Combination of the antivascular agent ZD6126 with hypoxic cytotoxin treatment, with reference to the effect on quiescent tumor cells and the dependency on p53 status of tumor cells.
Masunaga S; Nagasawa H; Uto Y; Hori H; Ohnishi K; Takahashi A; Ohnishi T; Suzuki M; Nagata K; Kinashi Y; Ono K
Oncol Rep; 2005 Aug; 14(2):393-400. PubMed ID: 16012721
[TBL] [Abstract][Full Text] [Related]
20. Tumor-host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds.
Giavazzi R; Bani MR; Taraboletti G
Cancer Metastasis Rev; 2007 Dec; 26(3-4):481-8. PubMed ID: 17896168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]